{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wang HY"],"funding":["National Natural Science Foundation of China","Natural Science Foundation of Guangdong Province"],"pagination":["973-982"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8524032"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["53(4)"],"pubmed_abstract":["<h4>Purpose</h4>Current variability in methods for tumor mutational burden (TMB) estimation and reporting demonstrates the urgent need for a homogeneous TMB assessment approach. Here, we compared TMB distributions in different cancer types using two customized targeted panels commonly used in clinical practice.<h4>Materials and methods</h4>TMB spectra of 295- and 1021-gene panels in multiple cancer types were compared using targeted next-generation sequencing (NGS). The TMB distributions across a diverse cohort of 2,332 cancer cases were then investigated for their associations with clinical features. Treatment response data were collected for 222 patients who received immune-checkpoint inhibitors (ICIs) and their homologous recombination DNA damage repair (HR-DDR) and programmed death-lig"],"journal":["Cancer research and treatment"],"pubmed_title":["Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing."],"pmcid":["PMC8524032"],"funding_grant_id":["81602468","2020A1515010313"],"pubmed_authors":["Yang XH","Li YQ","He Y","Long YK","Zhang X","Wang F","Deng L","Tang T","Feng YF","Wang HY"],"additional_accession":[]},"is_claimable":false,"name":"Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing.","description":"<h4>Purpose</h4>Current variability in methods for tumor mutational burden (TMB) estimation and reporting demonstrates the urgent need for a homogeneous TMB assessment approach. Here, we compared TMB distributions in different cancer types using two customized targeted panels commonly used in clinical practice.<h4>Materials and methods</h4>TMB spectra of 295- and 1021-gene panels in multiple cancer types were compared using targeted next-generation sequencing (NGS). The TMB distributions across a diverse cohort of 2,332 cancer cases were then investigated for their associations with clinical features. Treatment response data were collected for 222 patients who received immune-checkpoint inhibitors (ICIs) and their homologous recombination DNA damage repair (HR-DDR) and programmed death-lig","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2025-04-19T06:08:05.87Z","creation":"2025-04-19T06:08:05.87Z"},"accession":"S-EPMC8524032","cross_references":{"pubmed":["33677848"],"doi":["10.4143/crt.2020.798"]}}